These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2855719)

  • 1. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D.
    Kishimoto C; Crumpacker CS; Abelmann WH
    Cardiovasc Res; 1988 Oct; 22(10):732-8. PubMed ID: 2855719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice.
    Matsumori A; Tomioka N; Kawai C
    Am Heart J; 1988 Jun; 115(6):1229-32. PubMed ID: 2837073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model.
    Matsumori A; Crumpacker CS; Abelmann WH
    J Am Coll Cardiol; 1987 Jun; 9(6):1320-5. PubMed ID: 3034992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis.
    Padalko E; Nuyens D; De Palma A; Verbeken E; Aerts JL; De Clercq E; Carmeliet P; Neyts J
    Antimicrob Agents Chemother; 2004 Jan; 48(1):267-74. PubMed ID: 14693549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of oxygen derived free radicals in the pathogenesis of coxsackievirus B3 myocarditis in mice.
    Hiraoka Y; Kishimoto C; Takada H; Kurokawa M; Ochiai H; Shiraki K; Sasayama S
    Cardiovasc Res; 1993 Jun; 27(6):957-61. PubMed ID: 8221785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice.
    Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
    Cardiovasc Res; 1992 Oct; 26(10):956-61. PubMed ID: 1336713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of granulocyte colony-stimulating factor upon coxsackievirus B3 myocarditis in mice.
    Hiraoka Y; Kishimoto C; Takada H; Suzaki N; Shiraki K
    Eur Heart J; 1995 Dec; 16(12):1900-6. PubMed ID: 8682024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells.
    Kishimoto C; Takada H; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
    Cardiovasc Res; 1993 Feb; 27(2):243-8. PubMed ID: 8386064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of T lymphocytes in the pathogenesis of Coxsackie virus B3 heart disease.
    Hashimoto I; Tatsumi M; Nakagawa M
    Br J Exp Pathol; 1983 Oct; 64(5):497-504. PubMed ID: 6315043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of naloxone, an opiate receptor antagonist, on coxsackievirus B3 myocarditis in the mouse.
    Kishimoto C; Takada H; Hiraoka Y; Shiraki K
    Cardiovasc Res; 1995 Jan; 29(1):80-4. PubMed ID: 7895243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.
    Dai K; Wang Y; Tai S; Ni H; Lian H; Yu Y; Liao W; Zheng C; Chen Q; Kuver A; Li J
    Cardiovasc Ther; 2018 Dec; 36(6):e12477. PubMed ID: 30380183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
    Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of effects of cyclosporine on myocardial lymphocyte subsets in Coxsackievirus B3 myocarditis in the aviremic stage.
    Kishimoto C; Abelmann WH
    Circ Res; 1989 Oct; 65(4):934-45. PubMed ID: 2551533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis.
    Kishimoto C; Thorp KA; Abelmann WH
    Circulation; 1990 Sep; 82(3):982-9. PubMed ID: 2168299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis.
    Takada H; Kishimoto C; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
    Heart Vessels; 1993; 8(2):59-66. PubMed ID: 8390975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coxsackievirus B3 myocarditis in C3H/HeJ mice: description of an inbred model and the effect of exercise on virulence.
    Kiel RJ; Smith FE; Chason J; Khatib R; Reyes MP
    Eur J Epidemiol; 1989 Sep; 5(3):348-50. PubMed ID: 2551723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis.
    Costanzo-Nordin MR; Reap EA; O'Connell JB; Robinson JA; Scanlon PJ
    J Am Coll Cardiol; 1985 Nov; 6(5):1078-82. PubMed ID: 2995470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice.
    Lutton CW; Gauntt CJ
    J Interferon Res; 1985; 5(1):137-46. PubMed ID: 2985716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colony-stimulating factors and coxackievirus B3 myocarditis in mice: macrophage colony-stimulating factor suppresses acute myocarditis with increasing interferon-alpha.
    Hiraoka Y; Kishimoto C; Takada H; Suzaki N; Shiraki K
    Am Heart J; 1995 Dec; 130(6):1259-64. PubMed ID: 7484779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successive infection of coxsackievirus B3 and encephalomyocarditis virus: an animal model of chronic myocarditis.
    Okada I; Matsumori A; Tomioka N; Kawai C
    J Pathol; 1992 Jul; 167(3):341-7. PubMed ID: 1325552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.